READ OUR LATEST NEWS
Recent News
June 19, 2024
35Pharma Announces Participation at Upcoming Investor Conferences
Montreal, QC, Canada (June 19, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it will be participating at the following investor conferences: Leerink Partners Private Company Connect Piper Sandler 2nd Annual Virtual Obesity Day Fireside Chat About 35Pharma 35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the […]
March 25, 2024
35Pharma Announces Oral Presentation at the 2024 American College of Cardiology Scientific Session
Montreal, QC, Canada (Mar 25, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) in Atlanta, GA, USA (April 6 – 8, 2024). The presentation will feature pre-clinical data on HS135, […]
February 1, 2024
35Pharma Announces Oral Presentation at the 2024 American Thoracic Society International Conference
35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at the 2024 American Thoracic Society (ATS) International Conference in San Diego, CA, USA (May 17 – 22, 2024). The presentation will feature data on HS135, the Company’s Phase 1 novel Activin […]
January 31, 2024
35Pharma Announces Participation at Upcoming Investor Conferences
Montréal, QC, Canada (Jan 31, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it will be participating at the following investor conferences: Evercore ISI’s 2024 Emerging Private Biotech Conference Leerink Partners Global Biopharma Conference 2024 About 35Pharma 35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment […]
January 25, 2024
35Pharma Appoints Guy Braunstein, MD, PhD, to its Board of Directors
Montréal, QC, Canada (Jan 25, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced the appointment of seasoned drug development executive Guy Braunstein, MD, PhD, to its Board of Directors. Graham Walmsley, MD, PhD, also joined the board as an observer. “Guy’s successful track record in rapidly progressing numerous agents from early […]
January 3, 2024
35Pharma Announces Clearance of Clinical Trial Application for HS135, Best-in-Class Activin and GDF Inhibitor
Montréal, QC, Canada (Jan 03, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it received a No Objection Letter from Health Canada for its Clinical Trial Application to initiate HS135-001, a Phase 1 study of HS135 in healthy volunteers. “Overactive Activin and GDF signalling is a genetically and clinically validated […]
